AOD9604 | 5 MG

AOD-9604 (also known as hGH Fragment 177-191 or Tyr-hGH177-191) is a synthetic hexadecapeptide (16-amino-acid fragment) derived from the C-terminal region of human growth hormone (hGH). It was originally developed as an investigational compound to retain the lipolytic (fat-breaking) properties of hGH while avoiding its broader effects on growth, IGF-1 elevation, insulin sensitivity disruption, or other hormonal side effects associated with full-length GH.

AOD-9604 is thought to act by stimulating lipolysis (breakdown of stored fat) in adipose tissue and inhibiting lipogenesis (new fat formation), potentially through mechanisms involving beta-3 adrenergic receptor pathways or direct modulation of fat cell metabolism—without significantly impacting GH receptors or systemic growth processes.

Potential human benefits (primarily from early-phase clinical trials, preclinical animal models showing fat reduction, and anecdotal reports in wellness, fitness, and metabolic research communities):

• Targeted fat loss support — early human trials (e.g., 12-week studies) reported modest weight/fat reductions (e.g., ~2-3 kg in some cohorts), with animal models demonstrating significant body weight/fat decreases and increased lipolytic activity in adipose tissue.
• Improved body composition — potential for preferential reduction of stubborn fat stores while preserving lean mass, appealing for metabolic optimization or recomposition goals.
• Metabolic and energy perks — hints of enhanced fat oxidation, energy expenditure, and metabolic flexibility without adverse effects on glucose tolerance or insulin sensitivity seen with full hGH.
• Joint and cartilage support — some preclinical observations suggest possible benefits for osteoarthritis or bone health via direct effects on osteoblasts or tissue repair pathways.
• General wellness advantages — anecdotal accounts often describe better energy levels, reduced fatigue, and support for fat metabolism without appetite changes, cortisol spikes, or other common GH-related disruptions.

Human evidence is mixed and limited: initial small trials showed promise for safety/tolerability and some fat loss, but later Phase 2b studies (including larger cohorts with diet/exercise controls) failed to demonstrate consistent, significant weight reduction, leading to discontinued development as an obesity drug. No large-scale, confirmatory trials have established efficacy for fat loss or other indications, and benefits remain largely preclinical or self-reported.

Important Notice:

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.